WO2004089898A1 - Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists - Google Patents
Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists Download PDFInfo
- Publication number
- WO2004089898A1 WO2004089898A1 PCT/IB2003/001288 IB0301288W WO2004089898A1 WO 2004089898 A1 WO2004089898 A1 WO 2004089898A1 IB 0301288 W IB0301288 W IB 0301288W WO 2004089898 A1 WO2004089898 A1 WO 2004089898A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- hex
- azabicyclo
- formula
- methylphenyl
- Prior art date
Links
- 0 *C(***N(*)[C@@]1[C@@]2[C@]1CN(*)C2)c1c(*)ccc(*)c1 Chemical compound *C(***N(*)[C@@]1[C@@]2[C@]1CN(*)C2)c1c(*)ccc(*)c1 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
Definitions
- This invention relates to derivatives of substituted azabicyclo hexanes.
- the compounds of this invention can function as muscarinic receptor antagonists, and can be used for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors.
- the invention also relates to a process for the preparation of the compounds of the present invention, pharmaceutical compositions containing the compounds of the present invention and the methods of treating the diseases mediated through muscarinic receptors.
- Muscarinic receptors as members of the G Protein Coupled Receptors are composed of a family of 5 receptor sub-types (Mi, M 2 , M 3 , M and M 5 ) and are activated by the neurotransmitter acetylcholine. These receptors are widely distributed on multiple organs and tissues and are critical to the maintenance of central and peripheral cholinergic neurotransmission. The regional distribution of these receptor sub-types in the brain and other organs has been documented.
- the Mi subtype is located primarily in neuronal tissues such as cereberal cortex and autonomic ganglia
- the M 2 subtype is present mainly in the heart where it mediates cholinergically induced bradycardia
- the M 3 subtype is located predominantly on smooth muscle and salivary glands (Nature. 1986; 323: 411; Science, 1987; 237: 527).
- Muscarinic agonists such as muscarine and pilocarpine and antagonists such as atropine have been known for over a century, but little progress has been made in the discovery of receptor subtype-selective compounds making it difficult to assign specific functions to the individual receptors.
- classical muscarinic antagonists such as atropine are potent bronchodilators, their clinical utility is limited due to high incidence of both peripheral and central adverse effects such as tachycardia, blurred vision, dryness of mouth, constipation, dementia, etc.
- the present invention provides substituted azabicyclo hexanes as muscarinic receptor antagonists which are useful as safe and effective therapeutic or prophylactic agents for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems, and a process for the syntheses of these compounds.
- the invention also provides pharmaceutical compositions containing the compounds, and which may also contain pharmaceutically acceptable carriers, excipients or diluents which are useful for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems.
- the invention also includes within its scope prodrugs of the compounds.
- prodrugs are functionalized derivatives of these compounds which readily get converted in vivo into the defined compounds.
- Conventional procedures for the selection and preparation of suitable prodrugs are known to the artisan of ordinary skill in the art.
- the invention also includes the ⁇ nantiomers, diastereomers, N-oxides, polymorphs, pharmaceutically acceptable salts and pharmaceutically acceptable solvates, esters, and metabolites of these compounds having the same type of activity.
- the invention further includes pharmaceutical compositions comprising the compounds of the present invention, their metabolites, esters, enantiomers, diastereomers, prodrugs, N-oxides, polymorphs, pharmaceutically acceptable salts or pharmaceutically acceptable solvates, in combination with a pharmaceutically acceptable carrier and optionally included excipients.
- Ar represents an aryl or a heteroaryl ring having 1-2 hetero atoms selected from the group consisting of oxygen, sulphur or nitrogen atoms, the aryl or heteroaryl rings may be unsubstituted or substituted by one to three substituents independently selected from lower alkyl (C ⁇ -C 4 ), trifluoromethyl, methylenedioxy, cyano, hydroxy, halogen (e.g. F, CI, Br, I), nitro, lower alkoxy (C ⁇ -C ), amino or lower alkylamino (C ⁇ -C 4 );
- substituents independently selected from lower alkyl (C ⁇ -C 4 ), trifluoromethyl, methylenedioxy, cyano, hydroxy, halogen (e.g. F, CI, Br, I), nitro, lower alkoxy (C ⁇ -C ), amino or lower alkylamino (C ⁇ -C 4 );
- Ri represents hydrogen, lower alkyl (C ⁇ -C 4 ), lower alkenyl (C ⁇ -C ), lower alkynyl (C1-C 4 ), aryl or aralkyl;
- R 2 represents hydrogen or lower alkyl (C ⁇ -C );
- A represents (CH 2 ) n or CO, wherein n is an integer in the range of 0 to 4;
- W represents (CH 2 ) P , wherein p represents 1 to 4;
- X represents O, S, NR or no atom, wherein R represents H or lower alkyl (C ⁇ -C 4 );
- Y represents CHR 5 CO, (CH 2 ) q or no atom, wherein R 5 represents hydrogen or methyl and q represents 1 to 4;
- R 3 and R are independently selected from hydrogen, straight chain or branched alkyl (Ci- C 4 ), cycloalkyl, CO 2 C(CH ) , optionally substituted aryl or aralkyl.
- a method for treatment or prophylaxis of an animal or a human suffering from a disease or disorder of the respiratory, urinary and gastrointestinal systems, wherein the disease or disorder is associated with muscarinic receptors comprising administering to a patient in need thereof, an effective amount of compounds as described above.
- a method for treatment or prophylaxis of an animal or a human suffering from a disease or disorder associated with muscarinic receptors comprising administering to a patient in need thereof, an effective amount of compounds as described above.
- a method for treatment or prophylaxis of an animal or a human suffering from a disease or disorder of the urinary system which induce urinary disorders such as urinary incontinence, lower urinary tract symptoms (LUTS), etc.; respiratory system such as bronchial asthma, chronic obstructive pulmonary disorders (COPD), pulmonary fibrosis, etc.; and gastrointestinal system such as irritable bowel syndrome, obesity, diabetes and gastrointestinal hyperkinesis with compounds as described above, wherein the disease or disorder is associated with muscarinic receptors, comprising administering to a patient in need thereof, an effective amount of compounds as described above.
- a process for preparing the compounds as described above comprising administering to a patient in need thereof, an effective amount of compounds as described above.
- the compounds of the present invention exhibit significant potency in terms of their activity, which was determined by in vitro receptor binding and functional assays and in vivo experiments using anaesthetized rabbit. The compounds that were found active in in vitro assay were tested in vivo. Some of the compounds of the present invention were found to be potent muscarinic receptor antagonists with high affinity towards M 3 receptors. Therefore, the present invention provides pharmaceutical compositions for treatment of diseases or disorders associated with muscarinic receptors. Compounds and compositions described herein can be administered orally or parentally.
- the compounds described herein may be prepared by the techniques well known in the art and familiar to the average synthetic organic chemist. In addition, the compounds described herein may be prepared by the following reaction sequence as depicted in Scheme I.
- Ar represents an aryl or a heteroaryl ring having 1-2 hetero atoms selected from the group consisting of oxygen, sulphur or nitrogen atoms, the aryl or heteroaryl rings may be unsubstituted or substituted by one to three substituents independently selected from lower alkyl (C ⁇ -C 4 ), trifluoromethyl, methylenedioxy, cyano, hydroxy, halogen (e.g., F, CI, Br, I), nitro, lower alkoxy (C ⁇ -C 4 ), amino or lower alkylamino (C ⁇ -C 4 );
- substituents independently selected from lower alkyl (C ⁇ -C 4 ), trifluoromethyl, methylenedioxy, cyano, hydroxy, halogen (e.g., F, CI, Br, I), nitro, lower alkoxy (C ⁇ -C 4 ), amino or lower alkylamino (C ⁇ -C 4 );
- Ri represents hydrogen, lower alkyl (C ⁇ -C 4 ), lower alkenyl (C ⁇ -C ), lower alkynyl (C ⁇ -C 4 ), aryl or aralkyl;
- R 2 represents hydrogen or lower alkyl (C ⁇ -C 4 );
- A represents (CH 2 ) n or CO, wherein n is an integer in the range of 0 to 4;
- W represents (CH 2 ) P , wherein p represents 1 to 4;
- X represents O, S, NR or no atom, wherein R represents H or lower alkyl (C ⁇ -C 4 );
- Y represents CHR 5 CO, (CH2) q or no atom, wherein R 5 represents hydrogen or methyl and q represents 1 to 4;
- R 3 and R 4 are independently selected from hydrogen, straight chain or branched alkyl (d- C ), cycloalkyl, CO 2 C(CH ) 3 , optionally substituted aryl or aralkyl;
- Q is a leaving group, for example, hydroxy, amino, O-tosyl, O-mestyl and halogen, in the presence of a condensing agent to give a protected compound of Formula IV, which on deprotection through reaction with a deprotecting agent gives the compound of Formula I.
- reaction of the compound of Formula II with a compound of Formula III to give compounds of Formula TV can be carried out in the presence of a suitable condensing agent, for example, l-(3-dimethylamino propyl)-3 -ethyl carbodiimide hydrochloride (EDC) and l,8-diazabicyclo[5.4.0]undec-7ene (DBU).
- a suitable condensing agent for example, l-(3-dimethylamino propyl)-3 -ethyl carbodiimide hydrochloride (EDC) and l,8-diazabicyclo[5.4.0]undec-7ene (DBU).
- the reaction of the compound of Formula II with a compound of Formula III to give compounds of Formula IV can be carried out in the presence of a base, for example, N-methyl morpholine (NMM), N-methyl-2-pyrrolidinone (NMP), sodium carbonate, potassium carbonate, potassium iodide, triethylamine and diisopropylamine.
- a base for example, N-methyl morpholine (NMM), N-methyl-2-pyrrolidinone (NMP), sodium carbonate, potassium carbonate, potassium iodide, triethylamine and diisopropylamine.
- reaction of the compound of Formula II with compounds of Formula III to give compounds of Formula TV can be carried out in a suitable solvent, for example, N,N- dimethylformamide, dimethylsulphoxide, toluene, xylene, methanol and dichloromethane at a temperature ranging from about 0° C to about 140° C.
- a suitable solvent for example, N,N- dimethylformamide, dimethylsulphoxide, toluene, xylene, methanol and dichloromethane
- deprotection of the compound of Formula IV to give compounds of Formula I can be carried out with a suitable deprotecting agent, for example, palladium on carbon, trifluoroacetic acid (TFA) and hydrochloric acid.
- a suitable deprotecting agent for example, palladium on carbon, trifluoroacetic acid (TFA) and hydrochloric acid.
- the compounds of Formula II can be prepared by the reaction between p-methyl phenol with cinnamic acid to give the cyclized pyranone product which is then reacted with alkyl or aryl halide in a suitable base such as potassium carbonate in methanol. The resulting compound is finally hydrolyzed.
- the compounds of Formula II can also be prepared by the method as described in European patent application EP 0325571.
- compositions disclosed may be administered to an animal for treatment orally, or by a parenteral route.
- Pharmaceutical compositions disclosed herein can be produced and administered in dosage units; each unit containing a certain amount of at least one compound described herein and/or at least one physiologically acceptable addition salt thereof.
- the dosage may be varied over extremely wide limits as the compounds are effective at low dosage levels and relatively free of toxicity.
- the compounds may be administered in the low micromolar concentration, which is therapeutically effective, and the dosage may be increased as desired up to the maximum dosage tolerated by the patient.
- the present invention also includes the enantiomers, diastereomers, N-oxides, polymorphs, solvates and pharmaceutically acceptable salts of these compounds as well as metabolites having the same type of activity.
- the present invention further includes pharmaceutical composition comprising the molecules of Formula I or metabolites, enantiomers, diastereomers, N-oxides, polymorphs, solvates or pharmaceutically acceptable salts thereof, in combination with pharmaceutically acceptable carrier and optionally included excipients.
- the compound, 3-benzyl-3-azabicylo[3.1.0]hex-6-yl-2-chloroacetamide, 150 g, 0.65 mmole, leq prepared by reacting 3-benzyl-3-azabicylo[3.1.0]hex-6-yl amine with 2- chloroacetyl chloride.
- the compound 3-benzyl-3-azabicyclo[3.1.0]hex-6-ylamine in turn, can be prepared following the procedure of T. F. Braish et al., Synlett 1996, 1100) was dissolved in xylene.
- the compound, 3-benzyl-3-azabicyclo[3.1.0]hexa-6-yl-2-chloroacetamide, 150 mg, 0.565 mmole prepared by reacting 3-benzyl-3-azabicylo[3.1.0]hex-6-yl amine with 2- chloroacetyl chloride.
- the compound 3-benzyl-3-azabicyclo[3.1.0]hex-6-yl amine in turn, can be prepared by following the procedure of T. F. Braish et al., Synlett 1996, 1100) was dissolved in xylene.
- Step a The compound, 2-hydroxy-5-methylphenyl-3-phenyl-propanoic acid (520 mg, 2 mmole) was dissolved in dimethylformamide (9 ml). To the reaction mixture, 3-benzyl-3- azabicyclo[3.1.0]hex-6-yl amine (prepared following the procedure of T.F. Braish et. al., Synlett 1996, 1100) (376 mg, 2mmole) was added and the resulting reaction mixture was cooled to 0°C. To this, N-methyl morpholine (0.265 ml) and 1-hydroxy benzotriazole, HOBT (337 mg) were added and stirred for 10 minutes at 0°C.
- Step b The compound, N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl)-3-(2-hydroxy-5- methylphenyl)-3-phenyl-propionamide (200 mg, 0.47 mmole, leq) was dissolved in methanol (25 ml) and 10% palladium on carbon (50 mg) was added. The reaction mixture was hydrogenated for 2 hrs at 50 Psi. The reaction mixture was filtered over celite pad, the filtrate was concentrated and dissolved in dichloromethane. It was washed with brine, dried over sodium sulphate and concentrated under reduced pressure to yield the title compound.
- Step a The compound, 2-methoxy-5-methylphenyl-3-phenyl propanoic acid (270 mg, 1 mmole, 1 eq) was dissolved in dimethylformamide. To the reaction mixture, 3-benzyl-3- azabicyclo[3.1.0]hex-6-yl-amine (prepared following the procedure of T.F. Braish et. al., Synlett 1996, 1100) (188 mg, 1 mmole) was added and the resulting reaction mixture was cooled to 0°C. To this, N-methyl morpholine (0.132 ml) and hydroxy benzotriazole (163 mg) were added and stirred for 10 minutes at 0°C.
- Step b The compound, N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl)-3-(2-methoxy-5- methylphenyl)-3-phenyl propionamide was dissolved in methanol (15 ml), 200 mg of 10% palladium on carbon was added. The hydrogenation was continued for 4 hrs at 60 psi.
- Step a The compound, 3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-(4-bromobutyl)-carbamic acid t-butyl ester, 211.5 mg, 0.5 mmole, 1 eq (prepared by reacting boc-protected 3- benzyl-3-azabicylo[3.1.0]hex-6-yl amine, which in turn, was prepared following the procedure of T.F. Braish et al., Synlett, 1996, 1100, with l-bromo-3-chloropropane) was dissolved in xylene (15 ml).
- Step b The compound obtained above was dissolved in methanol (30 ml). To this, palladium on carbon (10%) was added. The resulting reaction mixture was hydrogenated at 60psi for 4 hrs. The reaction mixture was filtered over celite pad. The filtrate was dried, concentrated to yield the title compound.
- Step a The compound, 3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-(4-bromobutyl)-carbamic acid t-butyl ester, 211.5 mg, 0.5 mmole, 1 eq (prepared by reacting boc-protected 3- benzyl-3-azabicylo[3.1.0]hex-6-yl amine, which in turn, was prepared following the procedure of T. F. Braish et al., Synlett, 1996, 1100, with l-bromo-3-chloropropane) was dissolved in xylene (15 ml).
- This compound was prepared in the same way as step (a) of Example 5 by using 3-(2- benzyloxy-5-methylphenyl)-3 -phenyl propionic acid (260 mg, 0.75 mmole, 1.5 eq) instead of 3-(2-methoxy-5-methylphenyl)-3-phenyl propionic acid.
- the compound, N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl)-3-(2-methoxy-5-methylphenyl)- 3 phenyl-propionamide was prepared in a same way as in Example 11 by using 3-(2- methoxy-5-methylphenyl)-3-phenyl-propionic acid (270 mg, 1 mmole, 1 eq) instead of 3- (2-hydroxy-5-methylphenyl)-3-phenyl propionic acid.
- This compound was prepared following the procedure as described in Example 15 by using toluene-4-sulphonic acid-3-(2-hydroxy-5-methylphenyl)-3-phenylpropyl ester instead of toluene-4-sulphonic acid-3-(2-methoxy-5-methylphenyl)-3-phenylpropyl ester.
- test compounds for M 2 and M 3 muscarinic receptor subtypes were determined by [ 3 H] -N-methyl scopolamine binding studies using rat heart and submandibular gland, respectively as described by Moriya et al., (Life Scj 1999,64(25): 2351-2358).
- Membrane preparation Submandibular glands and heart were isolated and placed in ice cold homogenizing buffer (HEPES 20 mM, 10 mM EDTA, and pH 7.4) immediately after sacrifice. The tissues were homogenized in 10 volumes of homogenizing buffer and the homogenate was filtered through two layers of wet gauze and filtrate was centrifuged at 500g for lOmin. The supernatant was subsequently centrifuged at 40.000g for 20 min. The pallet thus obtained was resuspended in same volume of assay buffer (HEPES 20 mM, EDTA 5 mM, pH 7.4) and were stored at -70°C until the time of assay.
- HEPES 20 mM, 10 mM EDTA, and pH 7.4 ice cold homogenizing buffer
- Ligand binding assay The compounds were dissolved and diluted in dimethylsulfoxide. The membrane homogenates (150-250 ⁇ g protein) were incubated in 250 ul of assay buffer (HEPES 20 mM, pH 7.4) at 24-25°C for 3hour. Non-specific binding was determined in the presence of 1 ⁇ M atropine. The incubation was terminated by vacuum filtration over GF/B fiber filters (Wallac). The filters were then washed with ice-cold 50 mM Tris HCI buffer (pH 7.4). The filter mats were dried and bound radioactivity retained on filters was counted. The IC 50 & Kd were estimated by using the non-linear curve- fitting program using G Pad Prism software.
- Ki IC 50 /(1+L/Kd), where L is the concentration of [ 3 H]NMS used in the particular experiment.
- pKi -log Ki
- the bladder was cut into longitudinal strips (3 mm wide and 5-6 mm long) and mounted in 10 ml organ baths at 30°C, with one end connected to the base of the tissue holder and the other end connected to a polygraph through a force displacement transducer. Each tissue was maintained at a constant basal tension of 2 g and allowed to equilibrate for lhour during which the PSS was changed every 15 min. At the end of equilibration period, the stabilization of the tissue contractile response was assessed with 1 u mol/L of carbachol consecutively for 2-3 times. Subsequently, a cumulative concentration response curve to carbachol (10 "9 mol/L to 3 x 10 "5 mol/L) was obtained. After several washes, once the baseline was achieved, cumulative concentration response curve was obtained in the presence of NCE (NCE added 20 min. prior to the second CRC).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003214520A AU2003214520A1 (en) | 2003-04-09 | 2003-04-09 | Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists |
EP03710099A EP1618091A1 (en) | 2003-04-09 | 2003-04-09 | Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists |
US10/552,456 US7517905B2 (en) | 2003-04-09 | 2003-04-09 | Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists |
PCT/IB2003/001288 WO2004089898A1 (en) | 2003-04-09 | 2003-04-09 | Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IB2003/001288 WO2004089898A1 (en) | 2003-04-09 | 2003-04-09 | Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004089898A1 true WO2004089898A1 (en) | 2004-10-21 |
Family
ID=33156165
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2003/001288 WO2004089898A1 (en) | 2003-04-09 | 2003-04-09 | Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists |
Country Status (4)
Country | Link |
---|---|
US (1) | US7517905B2 (en) |
EP (1) | EP1618091A1 (en) |
AU (1) | AU2003214520A1 (en) |
WO (1) | WO2004089898A1 (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007039884A1 (en) | 2005-10-05 | 2007-04-12 | Ranbaxy Laboratories Limited | 3 -azabicyclooctane derivatives as muscarinic receptor antagonists |
WO2007077510A2 (en) | 2005-12-30 | 2007-07-12 | Ranbaxy Laboratories Limited | Muscarinic receptor antagonists |
WO2007110782A1 (en) | 2005-12-30 | 2007-10-04 | Ranbaxy Laboratories Limited | Muscarinic receptor antagonists |
WO2008010238A2 (en) * | 2006-07-21 | 2008-01-24 | Lupin Limited | Antidiabetic azabicyclo [3. 1. 0] hexan compounds |
WO2008117229A1 (en) * | 2007-03-23 | 2008-10-02 | Ranbaxy Laboratories Limited | Muscarinic receptor antagonists |
US7446123B2 (en) | 2003-04-11 | 2008-11-04 | Ranbaxy Laboratories Limited | Azabicyclo derivatives as muscarinic receptor antagonists |
US7544708B2 (en) | 2002-07-08 | 2009-06-09 | Ranbaxy Laboratories Limited | Azabicyclo derivatives as muscarinic receptor antagonists |
EP2130830A1 (en) | 2008-06-03 | 2009-12-09 | Ranbaxy Laboratories Limited | Muscarinic receptor antagonists |
WO2019152809A1 (en) | 2018-02-02 | 2019-08-08 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006117754A1 (en) * | 2005-05-03 | 2006-11-09 | Ranbaxy Laboratories Limited | 3,6-disubstituted azabicyclo [3.1.0] hexane derivatives as muscarinic receptor antagonists |
IL273924B2 (en) | 2017-10-20 | 2024-07-01 | Univ Vanderbilt | Antagonists of the muscarinic acetylcholine receptor m4 |
US11352344B2 (en) | 2017-10-31 | 2022-06-07 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993016048A1 (en) * | 1992-02-05 | 1993-08-19 | Fujisawa Pharmaceutical Co., Ltd. | Substituted acetamide compound |
US5397800A (en) * | 1990-09-13 | 1995-03-14 | Pfizer Inc. | Certain 1-azabicyclo[2.2.1]heptanes useful as muscarinic receptor antagonists |
US5559269A (en) * | 1992-11-06 | 1996-09-24 | Pharmacia Ab | 3,3-diphenylpropylamines, their use and preparation |
EP0823423A1 (en) * | 1995-04-28 | 1998-02-11 | Banyu Pharmaceutical Co., Ltd. | 1,4-disubstituted piperidine derivatives |
Family Cites Families (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2490714A (en) * | 1947-05-13 | 1949-12-06 | Du Pont | Preparation of diazoacetic esters |
NL124473C (en) | 1960-07-26 | |||
SE8800207D0 (en) | 1988-01-22 | 1988-01-22 | Kabivitrum Ab | NEW AMINES, THEIR USE AND MANUFACTURING |
US5001160A (en) * | 1988-04-28 | 1991-03-19 | Marion Laboratories, Inc. | 1-aryl-1-hydroxy-1-substituted-3-(4-substituted-1-piperazinyl)-2-propanones and their use in treatment of neurogenic bladder disorders |
GB8906166D0 (en) | 1989-03-17 | 1989-05-04 | Pfizer Ltd | Therapeutic agents |
WO1991002526A1 (en) | 1989-08-16 | 1991-03-07 | Pfizer Inc. | Azabicyclo quinolone carboxylic acids |
US5164402A (en) * | 1989-08-16 | 1992-11-17 | Pfizer Inc | Azabicyclo quinolone and naphthyridinone carboxylic acids |
US5281601A (en) * | 1989-12-12 | 1994-01-25 | Pfizer Inc. | Muscarinic receptor antagonists |
GB8928042D0 (en) | 1989-12-12 | 1990-02-14 | Pfizer Ltd | Muscarinic receptor antagonists |
FR2659323B1 (en) * | 1990-03-07 | 1992-06-12 | Synthelabo | DERIVATIVES OF 4- (AMINOMETHYL) PIPERIDINE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION. |
FI100051B (en) | 1992-02-18 | 1997-09-15 | Favorit Oy | composting |
JP3429338B2 (en) | 1992-07-27 | 2003-07-22 | 杏林製薬株式会社 | Novel arylglycinamide derivative and method for producing the same |
JPH06135958A (en) | 1992-10-28 | 1994-05-17 | Tanabe Seiyaku Co Ltd | Benzocycloheptene derivative and its production |
EP0613232B1 (en) | 1993-02-24 | 1997-04-23 | Siemens Aktiengesellschaft | Flyback converter power supply with a semi-conductor switch of low resistance voltage |
NO2005012I1 (en) | 1994-12-28 | 2005-06-06 | Debio Rech Pharma Sa | Triptorelin and pharmaceutically acceptable salts thereof |
CA2179574A1 (en) * | 1995-06-26 | 1996-12-27 | Tomomi Okada | Substituted piperidine derivative and medicine comprising the same |
AU7145996A (en) * | 1995-10-13 | 1997-04-30 | Banyu Pharmaceutical Co., Ltd. | Substituted heteroaromatic derivatives |
WO1997045414A1 (en) | 1996-05-31 | 1997-12-04 | Banyu Pharmaceutical Co., Ltd. | 1,4-disubstituted piperidine derivatives |
US6063808A (en) | 1996-07-01 | 2000-05-16 | Sepracor Inc. | Methods and compositions for treating urinary incontinence using enantiomerically enriched (S,S)-glycopyrrolate |
WO1998000132A1 (en) | 1996-07-01 | 1998-01-08 | Sepracor, Inc. | Methods and compositions for treating urinary incontinence using enantiomerically enriched (r,s)-glycopyrrolate |
WO1998000109A1 (en) | 1996-07-01 | 1998-01-08 | Sepracor, Inc. | Methods and compositions for treating urinary incontinence using enantiomerically enriched (s,r)-glycopyrrolate |
EP0932401A1 (en) | 1996-07-01 | 1999-08-04 | Sepracor, Inc. | Methods and compositions for treating urinary incontinence using enantiomerically enriched (r,r)-glycopyrrolate |
PE92198A1 (en) * | 1996-08-01 | 1999-01-09 | Banyu Pharma Co Ltd | DERIVATIVES OF FLUORINE-CONTAINED 1,4-PIPERIDINE |
KR20000057548A (en) | 1996-12-13 | 2000-09-25 | 알프레드 엘. 미첼슨 | Optically transmissive material and bond |
JP2002512625A (en) | 1997-05-29 | 2002-04-23 | メルク エンド カンパニー インコーポレーテッド | Heterocyclic amide compounds as cell adhesion inhibitors |
US6319920B1 (en) | 1998-02-27 | 2001-11-20 | Syntex (U.S.A.) Llc | 2-arylethyl-(piperidin-4-ylmethyl)amine derivatives |
TWI244481B (en) * | 1998-12-23 | 2005-12-01 | Pfizer | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy |
UA73543C2 (en) | 1999-12-07 | 2005-08-15 | Тераванс, Інк. | Urea derivatives, a pharmaceutical composition and use of derivative in the preparation of medicament for the treatment of disease being mediated by muscarine receptor |
ATE299494T1 (en) | 1999-12-07 | 2005-07-15 | Theravance Inc | CARBAMAT DERIVATIVES AS MUSCARINE RECEPTOR ANTONISTS |
SE9904765D0 (en) | 1999-12-23 | 1999-12-23 | Astra Ab | Pharmaceutically useful compounds |
AU2001260310B2 (en) | 2000-05-25 | 2007-04-05 | F. Hoffmann-La Roche Ag | Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists |
YU88902A (en) | 2000-05-25 | 2006-01-16 | F. Hoffmann-La Roche Ag. | Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists |
WO2002006241A1 (en) | 2000-06-14 | 2002-01-24 | Muscagen Limited | 1, 2, 3, 5 -tetrahydrobenzo`c!azepin-4-one derivatives having muscarinic antagonist activity |
HU229306B1 (en) | 2000-06-27 | 2013-10-28 | L V A T Lab Sa | Carbamates derived from arylalkylamines |
AU2001271027B2 (en) | 2000-07-11 | 2005-07-07 | Msd K.K. | Ester derivatives |
KR100869722B1 (en) | 2000-12-22 | 2008-11-21 | 알미랄 에이쥐 | Quinuclidine carbamate derivatives and their use as m3 antagonists |
ATE334128T1 (en) | 2000-12-28 | 2006-08-15 | Almirall Prodesfarma Ag | NEW QUINUCLIDENE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THESE COMPOUNDS |
AU2002314744A1 (en) * | 2001-04-17 | 2002-10-28 | Sepracor, Inc. | Thiazole and other heterocyclic ligands and use thereof |
EP1438309A1 (en) | 2001-10-17 | 2004-07-21 | Ucb, S.A. | Quinuclidine derivatives, processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors |
DE60224221T2 (en) | 2001-12-03 | 2008-12-11 | F. Hoffmann-La Roche Ag | AMINOTETRALIN DERIVATIVES, ANTAGONISTS OF MUSCARIN RECEPTORS |
DE60238709D1 (en) | 2001-12-03 | 2011-02-03 | Hoffmann La Roche | 4-PIPERIDINYL ALKYLAMINE DERIVATIVES, ANTAGONISTS OF MUSCARIN RECEPTORS |
CN1668585A (en) | 2002-07-08 | 2005-09-14 | 兰贝克赛实验室有限公司 | 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists |
US7265147B2 (en) | 2002-07-31 | 2007-09-04 | Ranbaxy Laboratories Limited | 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists |
US7410993B2 (en) | 2002-08-09 | 2008-08-12 | Ranbaxy Laboratories Limited | 3,6-disubstituted azabicyclo [3.1.0] hexane deriviatives useful as muscarinic receptor antagonists |
US7288562B2 (en) * | 2002-08-23 | 2007-10-30 | Ranbaxy Laboratories Limited | Fluoro and sulphonylamino containing 3,6-disubstituted azabicyclo (3.1.0) hexane derivatives as muscarinic receptor antagonists |
JP2006518707A (en) | 2002-12-10 | 2006-08-17 | ランバクシー ラボラトリーズ リミテッド | 3,6-Disubstituted azabicyclo [3.1.0] hexane derivatives as muscarinic receptor antagonists |
ATE386738T1 (en) | 2002-12-23 | 2008-03-15 | Ranbaxy Lab Ltd | FLAVAXATE DERIVATIVES AS MUSCARIN RECEPTOR ANTAGONISTS |
WO2004056767A1 (en) | 2002-12-23 | 2004-07-08 | Ranbaxy Laboratories Limited | 1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists |
AU2002356369A1 (en) | 2002-12-23 | 2004-07-14 | Ranbaxy Laboratories Limited | Xanthine derivatives as muscarinic receptor antagonists |
US7488748B2 (en) | 2003-01-28 | 2009-02-10 | Ranbaxy Laboratories Limited | 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists |
WO2004069835A1 (en) | 2003-02-07 | 2004-08-19 | Ranbaxy Laboratories Limited | Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists |
AU2003214535B2 (en) | 2003-04-10 | 2009-09-03 | Ranbaxy Laboratories Limited | Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists |
EP1615887A1 (en) | 2003-04-10 | 2006-01-18 | Ranbaxy Laboratories, Ltd. | Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists |
WO2004089900A1 (en) * | 2003-04-11 | 2004-10-21 | Ranbaxy Laboratories Limited | Azabicyclo derivatives as muscarinic receptor antagonists |
WO2005092341A1 (en) | 2004-03-22 | 2005-10-06 | Ranbaxy Laboratories Limited | Combination therapy for lower urinary tract symptoms |
WO2006003587A2 (en) | 2004-07-01 | 2006-01-12 | Ranbaxy Laboratories Limited | Solid oral dosage forms of azabicyclo derivatives |
EP1796667A2 (en) | 2004-09-27 | 2007-06-20 | Ranbaxy Laboratories Limited | Muscarinic receptor antagonists |
US20100035954A1 (en) | 2004-12-15 | 2010-02-11 | Mohammad Salman | Acid addition salts of muscarinic receptor antagonists |
-
2003
- 2003-04-09 AU AU2003214520A patent/AU2003214520A1/en not_active Abandoned
- 2003-04-09 WO PCT/IB2003/001288 patent/WO2004089898A1/en not_active Application Discontinuation
- 2003-04-09 US US10/552,456 patent/US7517905B2/en not_active Expired - Fee Related
- 2003-04-09 EP EP03710099A patent/EP1618091A1/en not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5397800A (en) * | 1990-09-13 | 1995-03-14 | Pfizer Inc. | Certain 1-azabicyclo[2.2.1]heptanes useful as muscarinic receptor antagonists |
WO1993016048A1 (en) * | 1992-02-05 | 1993-08-19 | Fujisawa Pharmaceutical Co., Ltd. | Substituted acetamide compound |
US5559269A (en) * | 1992-11-06 | 1996-09-24 | Pharmacia Ab | 3,3-diphenylpropylamines, their use and preparation |
EP0823423A1 (en) * | 1995-04-28 | 1998-02-11 | Banyu Pharmaceutical Co., Ltd. | 1,4-disubstituted piperidine derivatives |
Non-Patent Citations (1)
Title |
---|
ANDERSSON P G ET AL: "ASYMMETRIC TOTAL SYNTHESIS OF (+)-TOLTERODINE, A NEW MUSCARINIC RECEPTOR ANTAGONIST, VIA COPPER-ASSISTED ASYMMETRIC CONJUGATE ADDITION OF ARYL GRIGNARD REAGENTS TO 3-PHENYL-PROP-2-ENOYL-OXAZOLIDINONES", JOURNAL OF ORGANIC CHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, US, vol. 63, no. 22, 1998, pages 8067 - 8070, XP001037685, ISSN: 0022-3263 * |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7544708B2 (en) | 2002-07-08 | 2009-06-09 | Ranbaxy Laboratories Limited | Azabicyclo derivatives as muscarinic receptor antagonists |
US7446123B2 (en) | 2003-04-11 | 2008-11-04 | Ranbaxy Laboratories Limited | Azabicyclo derivatives as muscarinic receptor antagonists |
WO2007039884A1 (en) | 2005-10-05 | 2007-04-12 | Ranbaxy Laboratories Limited | 3 -azabicyclooctane derivatives as muscarinic receptor antagonists |
WO2007077510A2 (en) | 2005-12-30 | 2007-07-12 | Ranbaxy Laboratories Limited | Muscarinic receptor antagonists |
WO2007110782A1 (en) | 2005-12-30 | 2007-10-04 | Ranbaxy Laboratories Limited | Muscarinic receptor antagonists |
WO2008010238A2 (en) * | 2006-07-21 | 2008-01-24 | Lupin Limited | Antidiabetic azabicyclo [3. 1. 0] hexan compounds |
GB2454615A (en) * | 2006-07-21 | 2009-05-13 | Lupin Ltd | Antidiabetic azabicyclo (3.1.0) hexan compounds |
WO2008010238A3 (en) * | 2006-07-21 | 2008-04-17 | Lupin Ltd | Antidiabetic azabicyclo [3. 1. 0] hexan compounds |
WO2008117229A1 (en) * | 2007-03-23 | 2008-10-02 | Ranbaxy Laboratories Limited | Muscarinic receptor antagonists |
EP2130830A1 (en) | 2008-06-03 | 2009-12-09 | Ranbaxy Laboratories Limited | Muscarinic receptor antagonists |
WO2019152809A1 (en) | 2018-02-02 | 2019-08-08 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
JP2021513519A (en) * | 2018-02-02 | 2021-05-27 | ヴァンダービルト ユニバーシティー | Muscarinic acetylcholine receptor M4 antagonist |
EP3746421A4 (en) * | 2018-02-02 | 2021-10-27 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
US11414406B2 (en) | 2018-02-02 | 2022-08-16 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
JP7352294B2 (en) | 2018-02-02 | 2023-09-28 | ヴァンダービルト ユニバーシティー | Antagonist of muscarinic acetylcholine receptor M4 |
Also Published As
Publication number | Publication date |
---|---|
EP1618091A1 (en) | 2006-01-25 |
US7517905B2 (en) | 2009-04-14 |
AU2003214520A1 (en) | 2004-11-01 |
US20060281805A1 (en) | 2006-12-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7399779B2 (en) | 3,6-disubstituted azabicyclo [3.1.0] hexane derivatives useful as muscarinic receptor antagonists | |
US7265147B2 (en) | 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists | |
US7517905B2 (en) | Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists | |
US20070021487A1 (en) | Azabicyclo derivatives as muscarinic receptor antagonists | |
AU2003214535B2 (en) | Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists | |
US7501443B2 (en) | Flavaxate derivatives as muscarinic receptor antagonists | |
US20070010568A1 (en) | Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists | |
US7465751B2 (en) | 1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists | |
CA2511726A1 (en) | Xanthine derivatives as muscarinic receptor antagonists | |
US7410993B2 (en) | 3,6-disubstituted azabicyclo [3.1.0] hexane deriviatives useful as muscarinic receptor antagonists | |
US7560479B2 (en) | 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003710099 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003710099 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006281805 Country of ref document: US Ref document number: 10552456 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10552456 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2003710099 Country of ref document: EP |